Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

CLDN18.2 Targeted 68Ga-PMD22 PET Imaging in Patients With Gastrointestinal Tumours

ID
Name
PUMCH-PMD22
Description
To investigate the ability of the CLDN18.2-targeted 68Ga-PMD22 tracer to detect CLDN18.2 expression in patients with gastric and colorectal cancer and other gastrointestinal tumours.
Trial arms
Trial start
2023-05-28
Estimated PCD
2023-08-31
Trial end
2023-08-31
Status
Recruiting
Phase
Early phase I
Treatment
Intravenous injection of 68Ga-PMD22
68Ga-PMD22 were intravenous injected into the patients before PET/CT scans
Arms:
68Ga-PMD22 PET/CT dynamic scan, 68Ga-PMD22 PET/CT scan at one time
Other names:
68Ga-PMD22
Size
10
Primary endpoint
Dosimetric distribution of radiopharmaceuticals
2 months
Standardized uptake value
2 months
Eligibility criteria
Inclusion Criteria: * In the near future (within 2 months), patients who plan to undergo puncture biopsy or undergo tumor surgical treatment or are clinically highly suspected of cancer (including primary and tumor recurrence and metastasis) * Able to understand and voluntarily sign informed consent forms, with good compliance Exclusion Criteria: * Severe abnormalities in liver and kidney function * Suffering from claustrophobia or other mental illnesses * Pregnant and lactating women
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}}
Updated at
2023-07-10

1 organization

1 product

1 indication

Organization
Peking Union Medical College Hospital
Product
68Ga-PMD22
Indication
Gastrointestinal Cancer